The Nucleic Acid Core Facility is located in the Department of Gastrointestinal Oncology and Digestive Diseases in a 500 feet/2 laboratory. The Facility was created in the fall of 1996 through a CCSG supplement in Human Cancer Genetics. The NACF is a centralized facility for extraction of high-quality DNA from peripheral blood leukocytes and cell lines by using an Applied Biosystems Model 341 Nucleic Acid Extractor. This allows for the rapid isolation of highly purified, high- molecular-weight DNA. M.D. Anderson Cancer Center has a wealth of patient and family resources for studies of cancer-susceptibility genes. Most DNA isolation techniques used by individual laboratories required significant technical support and take 3 or more days. A centralized automated facility capable of producing PCR-grade DNA overnight from peripheral blood or cell is a major improvement in efficiency. The facility will be expanded to provide PCR-based genetic testing of transgenic animals. Because the high degree of product purity provided by the Model 341 Nucleic Acid Extractor will not be necessary for this testing, a more crude but rapid extraction procedure will be used to isolate DNA from mouse tails. The DNA will be subjected to PCR by using primates specifically designed to detect the transgenes, and animals positive for the transgenes will be identified. A large number of transgenic animal lines from over 20 different laboratories at M.D. Anderson are currently under investigation. Conducting DNA extraction from transgenic animal tails and PCR-based genetic testing in one centralized facility will be more efficient than performing these tasks in individual laboratories, as it will allow automation of each step by the use of Beckman Biomek 2000 robotic arms and multiplex PCR.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-24S2
Application #
6217269
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
24
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Garg, Rachana; Blando, Jorge M; Perez, Carlos J et al. (2018) COX-2 mediates pro-tumorigenic effects of PKC? in prostate cancer. Oncogene 37:4735-4749
Flinn, Ian W; O'Brien, Susan; Kahl, Brad et al. (2018) Duvelisib, a novel oral dual inhibitor of PI3K-?,?, is clinically active in advanced hematologic malignancies. Blood 131:877-887
Subbiah, Ishwaria M; Tang, Chad; Rao, Arvind et al. (2018) Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget 9:28842-28848
Daver, Naval; Boddu, Prajwal; Garcia-Manero, Guillermo et al. (2018) Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 32:1094-1105
Bailey, Matthew H; Tokheim, Collin; Porta-Pardo, Eduard et al. (2018) Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173:371-385.e18
Ohri, Nisha; Sittig, Mark P; Tsai, Chiaojung Jillian et al. (2018) Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis. Cancer 124:482-490
Cao, Qizhen; Yan, Xinrui; Chen, Kai et al. (2018) Macrophages as a potential tumor-microenvironment target for noninvasive imaging of early response to anticancer therapy. Biomaterials 152:63-76
Vichaya, Elisabeth G; Dantzer, Robert (2018) Inflammation-induced motivational changes: Perspective gained by evaluating positive and negative valence systems. Curr Opin Behav Sci 22:90-95
Nguyen, Jennifer; Jiao, Jingjing; Smoot, Kristin et al. (2018) Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis. Oncotarget 9:29495-29507
Reddy, S M; Barcenas, C H; Sinha, A K et al. (2018) Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer 118:17-23

Showing the most recent 10 out of 12418 publications